undamentalytics Newsletter
Sign in

Viridian Therapeutics, Inc.\de cash flow statement

In fiscal 2025, Viridian Therapeutics, Inc.\de's operations generated −$276m of cash; it spent $495,000 on capital projects, leaving free cash flow of −$277m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−1−2−7−15−28−27−36−30−55−94−184−232−276−333
Depreciation and amortisation00000000001100
Stock-based pay—4302444142067424454
Capital spending00000000011102
Free cash flow−1−2−7−15−28−27−36−30−55−95−185−233−277−335
Free cash flow after stock pay—−7−10−15−31−31−40−33−69−114−252−275−321−389
Share buybacks———0——————————
Shares issued−1713——452011429215706358

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: VRDN vs WVECGEN vs VRDNRXRX vs VRDNASMB vs VRDN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Viridian Therapeutics, Inc.\de's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Viridian Therapeutics, Inc.\de.